bluebird bio (BLUE) Tops Q4 EPS by 76c, Updates on BLA Submission for Lovo-Cel for Sickle Cell Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
March 29, 2023 7:00 AM EDT- Continued strong commercial launch for ZYNTEGLO® and SKYSONA®; 7 patient starts (cell collections) across both programs to date -
- Update on Biologics License Application (BLA) submission for lovo-cel for sickle cell disease (SCD) -
- Management to host conference call today, March 29, 2023 at 8:00AM ET -
SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022 including recent... More
